设为首页收藏本站

中国病毒学论坛|我们一直在坚持!

 找回密码
 立即注册

QQ登录

只需一步,快速开始

搜索
热搜: 活动 交友 discuz
查看: 1614|回复: 0
打印 上一主题 下一主题

最新immunity文章,CTL如何控制HIV逃逸

[复制链接]

500

帖子

606

学分

97

金币

VIP荣誉会员

Rank: 9Rank: 9Rank: 9Rank: 9

积分
606
跳转到指定楼层
楼主
发表于 2015-2-2 10:31:18 | 只看该作者 回帖奖励 |倒序浏览 |阅读模式
旧帖链接:http://biosky.haotui.com/viewthr ... 6amp%3Btypeid%3D142
楼主:marine0425030

A Molecular Basis for the Control of Preimmune Escape Variants by HIV-Specific CD8+ T Cells


The capacity of the immune system to adapt to rapidly evolving viruses is a primary feature of effective immunity, yet its molecular basis is unclear. Here, we investigated protective HIV-1-specific CD8+ T cell responses directed against the immunodominant p24 Gag-derived epitope KK10 (KRWIILGLNK263-272) presented by human leukocyte antigen (HLA)-B∗2705. We found that cross-reactive CD8+ T cell clonotypes were mobilized to counter the rapid emergence of HIV-1 variants that can directly affect T cell receptor (TCR) recognition. These newly recruited clonotypes expressed TCRs that engaged wild-type and mutant KK10 antigens with similar affinities and almost identical docking modes, thereby accounting for their antiviral efficacy in HLA-B∗2705+ individuals. A protective CD8+ T cell repertoire therefore encompasses the capacity to control TCR-accessible mutations, ultimately driving the development of more complex viral escape variants that disrupt antigen presentation. New T cell clonotypes are recruited to counter TCR-accessible HIV mutations These T cells express TCRs that crossrecognize wild-type and mutant epitopes Crossreactive CD8+ T cells underpin anti-HIV efficacy in HLA-B∗27+ patients T cell efficacy ultimately drives escape mutations that impact antigen presentation.

http://www.cell.com/immunity/abstract/S1074-7613(13)00106-4
分享到:  QQ好友和群QQ好友和群 QQ空间QQ空间 腾讯微博腾讯微博 腾讯朋友腾讯朋友
收藏收藏 分享分享 支持支持 反对反对
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

QQ|论坛App下载|Archiver|小黑屋|中国病毒学论坛    

GMT+8, 2024-11-25 08:26 , Processed in 0.095407 second(s), 29 queries .

Powered by Discuz! X3.2

© 2001-2013 Comsenz Inc.

快速回复 返回顶部 返回列表